Department of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
Department of Cancer Epidemiology, Henan Office for Cancer Control and Research, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
Sci Rep. 2020 Feb 3;10(1):1735. doi: 10.1038/s41598-020-58692-2.
The role of definitive radiotherapy (dRT) and debulking surgery (DS) for patients with locally advanced, unresectable, Masaoka-Koga stage III thymomas was not well studied. Unresectable tumor refers to tumor that could not be completely resected because of invasion of surrounding organs. Consecutive patients with unresectable stage III thymomas between 2000 and 2017 were reviewed. According to the treatment intent and radiation dose, patients were categorized into a dRT group and a non-dRT group. The former group included patients who received radiotherapy at doses ≥ 54 Gy after DS or biopsy. The latter group included patients who did not receive radiotherapy and those who received a radiation dose < 54 Gy. A total of 82 patients were included. Compared with non-dRT, dRT significantly improved 5-year overall survival (OS, P = 0.003), progression-free survival (PFS, P = 0.008), and freedom from locoregional failure (FFLF, P < 0.001). Compared with biopsy alone, DS did not improve OS, PFS, FFLF. On multivariate analysis, dRT was an independent prognostic factor for OS (hazard ratio [HR]: 2.37, P = 0.024), PFS (HR: 2.40, P = 0.004), and FFLF (HR: 3.83, P = 0.001). In conclusion, dRT was an effective and beneficial treatment for patients with unresectable Masaoka-Koga stage III thymoma.
根治性放疗(dRT)和减瘤手术(DS)在局部晚期、不可切除、Masaoka-Koga 分期 III 期胸腺瘤患者中的作用尚未得到充分研究。不可切除的肿瘤是指由于周围器官的侵犯而无法完全切除的肿瘤。回顾了 2000 年至 2017 年间连续的不可切除 III 期胸腺瘤患者。根据治疗目的和放射剂量,患者分为 dRT 组和非 dRT 组。前者组包括在 DS 或活检后接受剂量≥54Gy 放疗的患者。后者组包括未接受放疗和接受剂量<54Gy 放疗的患者。共纳入 82 例患者。与非 dRT 相比,dRT 显著提高了 5 年总生存率(OS,P=0.003)、无进展生存率(PFS,P=0.008)和无局部区域失败生存率(FFLF,P<0.001)。与单独活检相比,DS 并未改善 OS、PFS、FFLF。多因素分析显示,dRT 是 OS(风险比 [HR]:2.37,P=0.024)、PFS(HR:2.40,P=0.004)和 FFLF(HR:3.83,P=0.001)的独立预后因素。总之,dRT 是治疗不可切除的 Masaoka-Koga 分期 III 期胸腺瘤患者的有效且有益的治疗方法。